HIV infecting a human cell. Credit: NIH

Researchers from the University of Montreal Hospital Research Center (CRCHUM) have identified cells that provide "safe houses" for the human immunodeficiency virus (HIV) during antiretroviral therapy (ART).

Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple therapy. In a study published in the journal Nature Communications, they show, in the cells of people living with HIV, how these therapies reveal the virus—until now hidden in the hollows of infected cells—to the immune system.

"We identified the mechanism by which anti-cancer immunotherapy 'awakens' the virus from its hiding places and reduces the size of HIV reservoirs in people on triple therapy. Although most of our experiments have been performed in vitro, our approach could lead to the development of new therapies," stated Nicolas Chomont, a CRCHUM researcher and Université de Montréal professor.

Feb 21 (Reuters) - U.S. drugmaker Merck & Co Inc <MRK.N> said on Thursday it would buy immunotherapy developer Immune Design Corp <IMDZ.O> for nearly $300 million to gain access to new cancer treatments.

Merck will pay $5.85 in cash for each share of Immune Design. Shares of Immune Design closed at $1.42 on Wednesday.

Kandi Technologies Group, Inc. (NASDAQ GS: KNDI), announced today that Kandi brand electric vehicle (“EV”) Model EX3 and Model K22 have been approved for importation and registration in the USA by the National Highway Traffic Safety Adminstration (“NHTSA”). More information can be found by visiting the NHTSA’s website at, clicking the “vPIC Decoder” link and entering 7KZ in the Vehicle Identification Number (“VIN”) field. This is another significant milestone after qualifying for a $7,500 U.S. Federal tax credit in October 2018. The NHTSA approval is an assurance that Kandi’s two EV models conform to NHTSA standards and are registered in the U.S.. The JV Company will begin the process of launching the Model EX 3 and Model K22 for the American market.

TORONTO, ON / ACCESSWIRE / February 20, 2019 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for desvenlafaxine extended-release tablets in the 50 and 100 mg strengths. The approved product is a generic equivalent of the branded product Pristiq® sold in the U.S. by Wyeth Pharmaceuticals, LLC ("Wyeth").

ALPHARETTA, Ga., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that it received notification from the U.S. Food and Drug Administration (FDA) that the Agency has accepted for review the New Drug Application (NDA) for XIPERE (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for the treatment of macular edema associated with uveitis. The FDA has determined that the application is sufficiently complete to permit a substantive review.